IN-VITRO AND IN-VIVO DETECTION OF FUNCTIONAL SOMATOSTATIN RECEPTORS IN CANINE INSULINOMAS

Ten dogs with hypoglycemia due to insulinomas were studied to assess t he expression of somatostatin receptors (SSTRs) in canine insulinomas and its potential diagnostic value. Methods: The response of circulati ng glucose and insulin concentrations to the subcutaneous administrati on of a somatostatin analog, octreotide, was measured. SSTRs were visu alized in vitro by autoradiography. [Iodine-125-Tyr(3)]-octreotide and [I-125-Tyr(11)]-somatostatin-14 (SRIF-14) were used as radioligands. SPECT was performed 6 hr after the injection of [In-111-DTPA-D-Phe(1)] -octreotide. Results: After subcutaneous injection of 50 mu g octreoti de, plasma glucose concentration rose from 2.3 +/- 0.2 mmol/liter to 3 .2 +/- 0.3 mmol/liter at 3.5 hr (p < 0.05) and plasma insulin concentr ation decreased from 451 +/- 135 pmol/liter to a nadir of 249 +/- 115 pmol/liter at 30 min (p < 0.05). In vitro autoradiography revealed tha t all primary insulinomas and their metastases had specific SSTRs for both [I-125-Tyr(3)]-octreotide and [I-125-Tyr(11)]-SRIF-14. Scatchard analysis of SSTR binding in the tumor tissue of one dog revealed high- affinity binding sites for [I-125-Tyr(3)]-octreotide (dissociation con stant (Kd) 1.7 nM, maximum binding capacity (Bmax) 499 fmol/mg membran e protein). The primary tumor and/or metastases in five of six dogs co uld be visualized and localized by SPECT with [In-111-DTPA-D-Phe(1)]-o ctreotide. In the remaining dog, multiple metastases ((3 mm) were foun d in the liver at necropsy, apparently too small to be visualized by S PECT. Conclusion: The in vitro autoradiography and ligand binding stud ies indicate that canine insulinomas express one type of SSTR. This is in contrast with findings in humans where, on the basis of ligand bin ding studies, different subtypes of SSTRs have been identified. The un iformity of SSTRs, their high frequency of expression and the high inc idence of metastatic disease make canine insulinomas very suitable for investigation of the value of SRIF analogs in the diagnosis and treat ment of metastasized endocrine pancreatic tumors.